VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Summary

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA is a medical facility located in Jamaica Plain, Massachusetts. This center is recognized for care of Post-Traumatic Stress Disorder, Lung Cancer, Chronic Obstructive Pulmonary Disease, Motor Skills, Traumatic Brain Injury and other specialties. VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA is involved with conducting 269 clinical trials across 337 conditions. There are 28 research doctors associated with this hospital, such as Marilyn L Moy, MD, David William Sparrow, DSc, Gyorgy Baffy, MD, and Jason L. Vassy, MD, MPH, SM.

Top PIs

Clinical Trials running at VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Prostate Cancer

Chronic Obstructive Pulmonary Disease

Motor Skills

Depression

Post-Traumatic Stress Disorder

Traumatic Brain Injury

Lung Cancer

Cardiovascular Disease

Cancer

Concussion

Copper PET Imaging

for Prostate Cancer

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Recruiting

2 awards

Phase 3

4 criteria

Systemic + Local Therapy

for Prostate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

Recruiting

1 award

Phase 2 & 3

3 criteria

Genetic Testing

for Prostate Cancer Screening

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

Recruiting

1 award

N/A